UCLA Invents Newsletter
Newsletter published by: UCLA OIP-ISR July 2014


Aug. 01, 2014
FirstFridays @OIP-ISR
Speaker:   Prof. Al Osborne, UCLA Anderson
Topic:  Corporate Governance for Entrepreneurs
Sept. 05, 2014
FirstFridays @OIP-ISR
Topic:  "Investor Secrets: What startup investors want... but don't tell you."

More Events



Fibrocell Announces Exclusive License with UCLA
Technologies from the UCLA collaboration and exclusive license agreements enable Fibrocell to expand its proprietary Personalized Biologics platform which uses human fibroblasts and stem cells from skin to create localized therapies that are compatible with the unique biology of each patient.

UCLA Startup, Kite Pharma, Raises $128M in IPO

Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced the pricing of its IPO of 7,500,000 shares of its common stock at a price to the public of $17.00 per share.

CytoVale Raises $4.3M Series A for Early Sepsis Detection

UCLA startup licensee, CytoVale Inc . has raised a $4.3 million Series A round to better-enable early detection of sepsis, a severe response to infection that leads to organ damage, deaths, and billions of dollars in health-care expenses.
Pathways Event

Faculty Inventors and CEOs Share Startup Advice at OIP-ISR Pathways to Commercialization Event
The panel of faculty entrepreneurs paired with their CEO’s offered the audience of aspiring entrepreneurs advice on the process, pitfalls and potential for transferring academic research to the marketplace.

Intellectual Property Announcements

New U.S. Patents Awarded

  • 8,759,296 - Bone morphogenic protein binding peptide  | S. Murray, et al.
  • 8,759,006 - PSCA: prostate stem cell antigen and distinguishing androgen. . . | R. Reiter, et al.
  • 8,755,493 - Apparatus for producing X-rays for use in imaging  | G. Travish, et al.
  • 8,754,034 - Structure-based design of peptide inhibitors of amyloid fibrillation  | D. Eisenberg, et al.
  • 8,753,660 - Activating extraction of demineralized bone matrix  | S. Murray, et al.
  • 8,742,152 - Preparation of metal-catecholate frameworks  | O. Yaghi, et al.
  • 8,742,139 - No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds  | J. Barrio, et al.
  • 8,741,306 - Kidney specific tumor vaccine directed against kidney tumor. . . | A. Belldegrun, et al.


New UCLA Technologies Available for Licensing



    From Our Previous Issue 
    • UC FY13 Report on Tech-Transfer:  UCLA #1 in Startups
    • UCLA Startup, ImaginAb, Raises $21 Million in Series B Financing
    • UCLA Innovation Featured at UC Tech Commercialization Forum
    • Roundup:  UCLA Startup Funding & IP Licensing Highlights
    • View More
    Career Opportunities at UCLA Startups

    C3 Jian
    • Research Associate (Microbiology and Diagnostics)
    • Laboratory Assistant
    • Vice President, Clinical Development
    • Senior Research Associate - Conjugation Chemistry and Process Development
    • Staff Research Associate I
    Kite Pharma
    • Sr. Process Engineer
    • Research Associate, Cell Culture
    • Director, Quality Assurance
    "I recently attended the UCLA Medical Device partnership conference. I am interested
    in directed research with UCLA research groups." - Sr. R&D Manager

    UCLA TechMatch

    UCLA's customized, automated TechMatch service connects UCLA innovation with
    industry research and technology licensing interests.  Subscribe today.
    UCLA Invents Newsletter, Vol. 2, No. 11

    How to Subscribe

    View Newsletter Archive

    Send editorial comments and corrections to:  
    Bob Nidever, Editor,  bnidever@research.ucla.edu

    Contributors: Neil Bajpayee, Ben Dibling, Howard Chang, Miles Gerson

    UCLA Invents is published by the UCLA Office of Intellectual Property & Industry Sponsored Research
    11000 Kinross Ave., Suite 200; Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu

    Copyright © 2014 The Regents of the University of California. All Rights Reserved.

    Share this